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Abstract
Background: We report the detailed development of biomarkers to predict the clinical outcome under dengue infection.
Transcriptional signatures from purified peripheral blood mononuclear cells were derived from whole-genome gene-
expression microarray data, validated by quantitative PCR and tested in independent samples.
Methodology/Principal Findings: The study was performed on patients of a well-characterized dengue cohort from Recife,
Brazil. The samples analyzed were collected prospectively from acute febrile dengue patients who evolved with different
degrees of disease severity: classic dengue fever or dengue hemorrhagic fever (DHF) samples were compared with similar
samples from other non-dengue febrile illnesses. The DHF samples were collected 2–3 days before the presentation of the
plasma leakage symptoms. Differentially-expressed genes were selected by univariate statistical tests as well as multivariate
classification techniques. The results showed that at early stages of dengue infection, the genes involved in effector
mechanisms of innate immune response presented a weaker activation on patients who later developed hemorrhagic fever,
whereas the genes involved in apoptosis were expressed in higher levels.
Conclusions/Significance: Some of the gene expression signatures displayed estimated accuracy rates of more than 95%,
indicating that expression profiling with these signatures may provide a useful means of DHF prognosis at early stages of
infection.
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Introduction
The dengue virus is a member of Flaviviridae family, genus
flavivirus with four antigenically distinct serotypes (DENV-1 to
DENV-4). Dengue virus infection is a global public health
concern, with an estimated incidence of 50–100 million cases of
dengue fever (DF), resulting in 500,000 clinical cases of life-
threatening dengue hemorrhagic fever syndrome (DHF) and
24,000 deaths per year [1]. DHF is characterized by vasculopathy,
which results in sudden plasma leakage that reduces the blood
volume and may result in hypovolemic shock, known as dengue
shock syndrome (DSS). There is no antiviral therapy to treat
dengue infection, neither are there means to prevent the
development of DHF.
During the acute febrile phase of infection, DF and DHF
patients display a very similar clinical picture. However at
defervescence (after 4 to 7 days of the beginning of the symptoms),
DHF patients start to present signs of circulatory disturbance [2],
which makes medical management a major challenge in endemic
areas. This is especially true during outbreaks when dengue cases
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7892typically over saturates the capacity of all medical points-of-care,
and results in shortage on the capacity to attend the regular
demand for medical assistance causing major disruptions on the
public health systems.
The World Health Organization [2] has established clinical
criteria to define DHF cases, but the difficulties of both fulfilling
these criteria and early identification of severe cases, make the
clinical management of severe forms of the disease even a greater
challenge [3,4]. Therefore, a search for new tools to predict patient
outcome is essential to facilitate the assessment of the need for
medical interventions.
The current concept underlining DHF immunopathology
relies on epidemiological evidence indicating an increased risk of
developing DHF in secondary dengue infections. This concept
led to the identification of biological mechanisms involving
antibody mediated enhancement (ADE), mediated by non-
neutralizing antibodies [5,6], as well as exacerbated activation
of cross-reactive T cell clones [7,8,9,10], both acquired after
primary infection. Some of the ‘‘markers’’ of dengue severity
found on peripheral blood that were correlated with plasma
leakage on DHF include several inflammatory cytokines,
chemokines and adhesion molecules that are expressed at high
levels [11,12,13,14,15,16,17], complement activation products
[18,19], increased frequency of activated cells [20,21] and large
number of cells undergoing apoptosis [9,22]. All these findings
have helped to advance the understanding of the immune
mechanisms involved in the development of DHF but none of
them were proven to be reliable or useful as biological markers
for clinical use.
DNA microarrays have been used as a tool to identify
‘‘signature genes’’ and predict successfully, patient outcome for
cancer [23,24] as well as for bacterial and viral infections [25,26].
Using this approach, some studies have shown that at the peak of
the disease, several genes are differentially expressed in dengue
patients presented with the more severe disease [27,28]. Hence, we
believe that an early gene expression signature differentiating the
mild from the severe clinical outcomes of dengue could be a useful
tool for developing biomarkers to predict clinical outcome, which
will facilitate the clinical management of dengue infected patients.
Here we report the analysis of gene-expression microarray data
of PBMC samples collected from DF and DHF patients during the
febrile phase of the disease. These data were used as the basis for
the development of reliable biomarkers to predict the clinical
outcome of dengue infection.
Methods
Dengue Cohort Design and Strategy for Functional
Genomic Studies
A cohort of acute febrile patients admitted on three hospitals in
the city of Recife, state of Pernambuco, Brazil, was established and
described elsewhere [29,30]. Briefly, sequential blood samples
were obtained at the day of admission, day 1, and at days 3, 5, 7,
15 and 30. Dengue cases (confirmed by either serology, RT-PCR
or virus isolation) were clinically classified according to the WHO
criteria into two classes: Dengue Fever (DF) and Dengue
Hemorrhagic Fever (DHF) [31]. All participants signed an
informed consent. This study, that included several methods
suitable for studies related to dengue immunopathology including
functional immunomics, was reviewed and approved by ethics
committee of Brazilian Ministry of Health CONEP: 4909; Process
nu 25000.119007/2002-03; CEP: 68/02. In addition, the Johns
Hopkins IRB also reviewed this study as protocol JHM-IRB-3: 03-
08-27-01.
The inclusion criterion for this functional genomic study was:
All the subjects enrolled had to have at least three medical visits
within the first two weeks of study enrollment. The dengue
patients had to have confirmed acute dengue 3 infection based on
RT-PCR/virus isolation and serology, be febrile at the time of the
first hospital visit (temp. above 38.5uC) and with more than
10610
6 PBMCs available for microarray analysis collected at the
first visit. Moreover, for DHF group, the samples must be collected
prior the onset of circulatory disturbances (hematocrit and levels of
serum albumin normal) and no signs of bleeding (tourniquet test
negative). Samples had to have clear definition of the clinical
outcome of either DF or DHF. A non-dengue group of patients
(ND) consisting of individuals with febrile infection of unknown
etiology with negative tests results for dengue by RT-PCR, virus
isolation and serology after at least 3 samples collected within the
first two weeks after enrollment. This group includes suspected
dengue cases collected during the same period as the dengue cases,
but for which dengue infection was not confirmed through either
RT-PCR/virus isolation or serology in at least three blood samples
collected at different days. The samples from DF, DHF and ND
patients were matched to avoid spurious associations with patient
age, gender, dengue infection history and days of symptoms
between the groups.
The functional genomic studies were performed on total RNA
extracted from PBMC purified from blood samples collected from
febrile patients at the time of their first medical visit. The samples
selected for this study were collected from 18 confirmed dengue 3,
genotype III cases and 8 control samples (ND group). None of the
DHF patients presented vasculopathy signs and symptoms at the
time the samples used in the functional genomic characterization
were collected. At the time of collection the patients referred
approximately 5 days of disease and the absence of fever was
reported two to three days after enrollment. Among the dengue
confirmed cases, 8 patients were characterized as DF and 10
patients were classified as DHF (Table 1).
Sample Processing for Genechip Hybridization
Blood samples from patients enrolled in this study were
collected in heparin vacutainer tubes (BD Vacutainer) and within
2 hours from the collection, PBMC samples were separated by
gradient density using Ficoll-Paque (Amersham Biosciences) and
cryopreserved in 10% (v/v) Dimethyl sulfoxide (DMSO; Sigma-
Aldrich) in inactivated fetal bovine sera (FBS; Hyclone). Four
million frozen cells were thawed and immediately lysed with Trizol
(Invitrogen) for total RNA extraction through chloroform
extraction and isopropyl alcohol precipitation following manufac-
turer’s protocol [gene expression using either fresh or frozen
PBMC were compared and shown to be similar, (data not shown)].
The total RNA was purified by using the RNeasy MinElute
Cleanup Kit (Qiagen) according to the manufacturer protocol and
quantified by spectrophotometry at 260 nm and 280 nm (UV
spectrum). Total RNA was used for cRNA synthesis through two-
cycle target labeling kit (Affymetrix) according to the manual
manufacturer. Briefly, RNA isolated from the PBMC was biotin-
labeled and hybridized to human oligonucleotide microarrays
(Affymetrix) by using a two-cycle methods of cDNA synthesis as
follow. On the first cycle, first-strand cDNA was prepared by using
a T7-(dT) primer and Superscript II reverse transcriptase
(Invitrogen) from 10 to 100 ng of cellular RNA. Second strand
synthesis was performed by using E. coli DNA polymerase I and
the double-stranded cDNA was used for in vitro transcription
(IVT) for cRNA amplification by using Megascript T7 kit
(Ambion). The product of this first cycle of reaction (cRNA) was
used for reverse transcription for synthesis of first and second
DHF Biomarker
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Dengue diagnosis
Patients Clinical Diagnosis Sex Age Days of Symptoms IgM IgG PCR/virus isolation
P330 DF F 40 4 Neg Pos Pos
P310 DF F 30 3 Neg Pos Pos
P331 DF M 45 6 Pos Pos Pos
P121 DF M 53 4 Neg Pos Pos
P129 DF F 29 5 Neg Pos Pos
P164 DF M 27 1 Neg Pos Pos
P171 DF M 44 5 Neg Pos Pos
P243 DF F 23 7 Pos Neg Pos
P277 DHF M 41 3 Neg Pos Pos
P307 DHF F 41 8 Pos Neg Pos
P125 DHF F 84 8 Pos Pos Pos
P128 DHF F 26 7 Pos Neg Pos
P145 DHF M 19 7 Pos Neg Pos
P165 DHF F 22 4 Neg Neg Pos
P206 DHF M 36 8 Pos Pos Pos
P235 DHF F 35 5 Pos Pos Pos
P102 DHF F 21 7 Pos Neg Pos
P111 DHF F 21 5 Pos Neg Pos
P317 ND M 41 4 Neg Neg Neg
P237 ND M 25 8 Neg Neg Neg
P239 ND M 47 4 Neg Neg Neg
P251 ND M 54 4 Neg Neg Neg
P195 ND F 23 6 Neg Neg Neg
P199 ND F 19 6 Neg Neg Neg
P216 ND F 30 2 Neg Neg Neg
P269 ND F 64 4 Neg Neg Neg
P430 DHF F 25 8 Neg Pos Neg
P586 DHF F 16 5 Pos Pos Pos
P557 DHF F 76 9 Pos Neg Pos
P549 DHF F 10 11 Pos Pos Neg
P543 DHF F 29 11 Pos Pos Neg
P586 DHF F 16 7 Pos Pos Pos
P414 DHF M 34 5 Neg - -
P305 DHF M 35 6 Pos Pos Pos
P677 DF F 69 8 Pos Pos Neg
P659 DF F 32 8 Pos Pos Neg
P650 DF F 58 8 Neg Pos Pos
P633 DF F 39 8 Pos Neg Neg
P634 DF F 27 8 Pos Pos Pos
P620 DF M 62 8 Pos Pos Neg
P600 DF M 52 8 Neg Pos Neg
P588 DF M 26 5 Neg Neg Pos
P310 DF F 30 3 Neg Pos Pos
In bold: samples used exclusively in the qPCR assays. DF: Dengue Fever; DHF: Dengue hemorrhagic fever; ND: Non-Dengue; M: male; F: female; Pos: positive; Neg:
negative; -: No information.
doi:10.1371/journal.pone.0007892.t001
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used for IVT for synthesis of biotin-labeled cRNA, which was
fragmented and sent to Microarray Core Facility at The Johns
Hopkins University for target hybridization to Human Genome
U133 Plus 2.0 DNA Chip (Affymetrix), staining and scanning.
Microarray Data Quality Control
The quality of the microarray data was assessed using several
criteria: visual inspection, noise/efficiency measurements, spike-in
controls, housekeeping gene expression, and RNA degradation
plots. Visual inspection based on the high-resolution. DAT files
did not reveal smudges or streaks, and the B2-oligo probes (e.g.,
chessboard patterns around edges and name of array) were also
visible. Noise/Efficiency measurements made by the Affymetrix
MAS 5.0 software that can be used to evaluate the quality of the
arrays are displayed in the Supplement material S1. Noise Q
factors, background, scaling factors, and the percentages of present
calls were similar across all arrays. Average background values
were below 100 for 20 of the 26 microarrays; scaling factors were
within three folds of each other, for 25 of the 26 microarrays; and
the percentages of present calls were around 40% or higher for 25
of the 26 arrays. None of the six arrays that presented high
background had a rate of present calls significantly below 40%. All
39-probe sets and middle probe sets for all 4 spike-in poly-A
control genes (dap, thr, phe, lys) were called present in all arrays, as
were all probe sets for the four prokaryotic hybridization control
genes (bioB, bioC, bioD, cre) and the human housekeeping genes
GAPDH (human glyceraldehyde-3-phosphate dehydrogenase) and
Beta-Actin. Furthermore, RNA degradation plots showing the
average intensity of probes indicate an acceptable levels in all
probe sets displayed (see in Supplement material S2).
Quantitative Real Time PCR for Microarray Validation
Four DF/DHF differentially expressed genes (MT2A, PSMB9,
C3aR1 and HLA-F) were selected for quantification by quanti-
tative real time PCR (qPCR). Genes were amplified and detected
using TaqManH gene expression assays with primers and probes
commercially designed (Applied Biosystems). RNA extraction was
performed according to the manufacturer’s manual for the
RNeasy Kit (Qiagen). Total RNA was reverse transcribed to
cDNA using SuperScript III First-strand Synthesis System for
qPCR (Invitrogen) using random hexamer primers according to
the manufacturer’s instructions. Quantitative real time PCR was
carried out on the ABI PRISM 7500 device (Applied Biosystems).
Beta-Actin was selected as endogenous control and all data were
normalized against it. The reactions were performed in triplicates
and included 2 ml of cDNA, primers (20 mM each) and 6.25 mMo f
the specific probe or commercially pre-designed Gene Expression
Assay Mix (Applied Biosystems), Human Beta-Actin (Applied
Biosystems), TaqMan Universal PCR Master Mix (Applied
Biosystems) and water added to a final volume of 25 ml. Triplicates
of non-template controls (NTC) were included each time qPCR
was undertaken. Cycle conditions were as follows: after an initial
2-min hold at 50uC and 10 minutes at 95uC, the samples were
cycled 40 times at 95uC for 15 sec and 60uC for 1 min. Baseline
and threshold for cycle threshold (Ct) calculation were set
manually with Sequence Detection Software version 1.4. The
efficiency of amplification (E) of a target molecule was calculated
from the slope of the standard curve (plot of Ct versus the negative
log10 concentration of the target) derived from the slopes
(E=10ˆ(21/Slope)21). For relative calculation the Delta Ct
method was used [ABI PRISMH 7000 Sequence Detection System
and Applied Biosystems 7500 Real-Time PCR System - User
Bulletin, Applied Biosystems] once all assays met the amplification
efficiency criteria of 100%610% [Application Note 127AP05-02].
Samples used in the qPCR assays are described on Table 1
(samples of ND patients and DHF patients number 105 and 112
were not used).
Statistical Analysis
Patient data quality-control, statistical analysis, and plotting were
carried out using Affymetrix MAS 5.0 software [32] and the open
source R statistical package, version 2.5.0 [33], and add-on libraries,
in particular the BioConductor library, version 1.16 [34]. Dendro-
grams and MDS plots were produced with the R functions ‘‘hclust’’
and ‘‘isoMDS’’, respectively, whereas heatmaps were obtained with
the functions ‘‘hset.emap’’ and ‘‘heatmap’’. All microarray data is
MIAME compliant and the raw data has been deposited in a
MIAMEcompliantdatabaseasaccessionnumber# GSE18090and
it is available at http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token=lpofdqcuugmwsng&acc=GSE18090. P-values corre-
sponding to two-tailed Welch’s two-sample t-tests were obtained
with the function ‘‘t.test’’. Functional category overrepresentation
analysis was performed with the performed with the EASE program
(Expression Analysis Systematic Explorer) at the DAVID Bioinfor-
matics resource website (http://david.abcc.ncifcrf.gov/) [35]. The
Linear Discriminant Analysis classification method implemented by
directly estimating the sample means and covariance matrices for
each diagnostic class [36]. Classification accuracy was estimated by
the method of bolstered resubstitution [37], which displays
good properties for gene-set selection in small-sample situations
[38,39]
Results
Detection and Variance Filters
After careful quality control analyses of each genechip,
Affymetrix MAS 5.0 software was used to analyze the data. From
54,675 gene transcripts on each of the 26 arrays, 12,299 were
called present (p-value ,0.04) on all arrays, whereas 20,365 were
not called present on any of the arrays. In order to retain only
promising genes and enable significant statistical analysis, we chose
to analyze the genes that were called present on at least 24 of the
26 arrays used in this study. This filter resulted in a total of 15,848
genes and among those, 3,549 genes (15,848212,299=3,549) that
were called absent on one or two arrays. Subsequently we applied
a variance filter to eliminate constitutive or housekeeping genes,
which retained the top 1/8 gene in variance out of 15,848 previous
genes, which resulted in 1981 ‘‘best’’ genes.
Exploratory Analysis
Figure 1 displays the dendrogram for the hierarchical clustering
of the 26 samples according to the expression of the 1981 genes
selected at the preprocessing stage. Average linkage and Pearson
correlation of log-transformed expression values were employed.
We can see that the samples fell into two major groups; the one on
the right contains only ND samples, and half (4) of the DF samples,
while the group on the left contains all the DHF samples, a couple
of ND samples (including one outlier, ND_199), and the other half
of the DF samples. This agrees with intuition, since the two most
different groups should be ND and DHF, with the DF samples
forming an intermediary group. This is confirmed by the 2-D and
3-D multidimensional scaling (MDS) plots for the 1981 selected
genes, displayed in Figures 2A and 2B. The dissimilarity measure
used was 12r, where r is Pearson correlation of log-transformed
values. Arrays were colored according to diagnostic class. It can be
seen that the DHF samples constitute a tighter cluster than the ND
samples, as expected since ND samples were obtained from patient
DHF Biomarker
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divided in two groups, one similar to the DHF samples, and
another not similar to DHF, and in fact closer in expression to
some of the ND samples (these are the two groups marked in
Figure 2A). The small stress values (13.52% in the 2-D case and
7.32% in the 3-D case), particularly in the 3D case, mean that the
underlying structure of the data is intrinsically a low-dimensional
one, which indicates that a small number of signature genes might
be able to account for the discriminatory content in the data.
Differential Expression Analysis
Statistical tests of differences between means (Welch two-sample
t-tests) were performed to show the most differentially expressed
mRNAs among the diagnostic groups. We considered four
comparisons among groups: DF vs. DHF samples; Dengue
(DF+DHF) vs. ND samples; DF vs. ND samples; DHF vs. ND
samples. The first comparison corresponds to the 18 samples that
come from dengue patients and is the most important comparison
for our purposes, as it discriminates between the severe
hemorrhagic form of dengue and the benign one. Important
genes used to characterize these two clinical outcomes were
gathered on Table 2. The ‘‘volcano plot’’ on Figure 3 and the
correspondent gene list on Table 3, show that p-values were well
correlated to fold changes in DF vs. DHF samples as well as for the
other comparisons (Supplement material S3). The largest
differences were observed in the comparison of DHF vs. ND, as
expected, followed by differences in (DHF+DF) vs. ND and DF vs.
ND. The critical differences in gene expression between DF and
DHF are the least pronounced. The top 40 genes with the most
significant p-values among the 1981 genes previously selected, for
each of the four comparisons, along with fold change values,
average signal intensity, and annotation from the DAVID
Bioinformatics Database at NIAID/NIH (http://david.abcc.
ncifcrf.gov/) can be accessed in the Supplement material S4.
Figure 4 shows the heatmap expression for the 40 top genes that
discriminate the DF and DHF samples, according to the Welch t-
test criterion, as well as the dendrogram of hierarch clustering and
MDS plot for the 40 top DF-DHF discriminatory genes. Table 4
displays the results of functional overabundance analysis of the list
of top 40 DF-DHF discriminatory genes performed with the EASE
program (Expression Analysis Systematic Explorer) at the DAVID
Bioinformatics resource website. The EASE analysis indicated the
enrichment of certain categories of genes. Five categories
presented significant scores (p,0.05) after Bonferroni correction
for multiple tests, including the ones involved on immune and
defense responses, response to biotic stimulus, copper/cadmium
binding and copper ion homeostasis. The EASE results for all 4
comparisons can be accessed in the Supplement material S5.
Identification of Classifier Genes
In addition to univariate gene selection by t-tests, we did
exhaustive feature selection (all possible combinations) of single,
pairs, and triplets of genes out of the prefiltered set of 1981 genes,
using Linear Discrimination Analysis as the classification rule, and
bolstered resubstitution as the error estimator (see Methods
section). Table 5 displays the top-ten 1-gene, 2-gene and 3-gene
classifiers, respectively, ranked by estimated classification error.
Supplement material S6 displays top-40 1-gene and 2-gene
classifiers as well as the top-100 3-gene classifiers, also ranked by
estimated error. There are 37 unique genes among the top-40
pairs, while there are 86 unique genes among the top 100 triplets.
The list of gene triplets is heavily dominated by the genes PSMB9,
MT2A, and LOC400368. In fact, only one triplet in the top 100
does not contain any of these three genes, namely (SFRS5,
PDCD4, MKNK2), which has an estimated error of 0.0383. The
average estimated error for the top classifiers was as follows: 1-gene
classifier (40)=0.163960.0286, 2-gene classifier (40)=0.06866
0.0096, 3-gene classifier (100)=0.039560.0040, which indicates
that classification with pairs is more accurate than with single
genes, while classification with triplets is more accurate than with
Figure 1. Dendrogram of hierarchical clustering considering 1981 genes.
doi:10.1371/journal.pone.0007892.g001
DHF Biomarker
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Feature selection with two genes and three genes has the potential
of ‘‘fetching’’ genes that cannot otherwise be found by using
univariate methods (such as t-tests). This can be seen from the list
of top two-gene classifiers. For example, we can see the gene for
the HLA-F (which is lower expressed in DHF than in DF, data not
shown). Figure 5 displays the plot of the best 2-gene classifier
found by exhaustive feature selection, consisting of the pair of
genes PSMB9 and MT2A. The estimated probability of error on
future data for this classifier, as determined by bolstered
Figure 2. Multidimensional scaling (MDS) plots for the 1981 selected genes. (A) 2-D MDS plot. (B) 3-D MDS plot. The elipses in (B)
depmarcate two major groups of samples (please see text).
doi:10.1371/journal.pone.0007892.g002
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Symbol Gene Title p-value Fold-change Average signal
RNF36 ring finger protein 36 0.000119 2.3447 6.7868
UBE2J1 ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) 0.000419 22.3147 7.3763
CD300A CD300a molecule 0.000864 2.1544 7.079
IGL@ Immunoglobulin lambda locus 0.001172 23.0718 6.3888
MT1X metallothionein 1X 0.001294 2.2122 7.5485
MAGED1 melanoma antigen family D, 1 0.001644 22.0342 7.0617
GBP1 guanylate binding protein 1, interferon-inducible, 67 kDa///guanylate binding
protein 1, interferon-inducible, 67 kDa
0.00216 1.9967 7.8344
VAMP3 vesicle-associated membrane protein 3 (cellubrevin) 0.002351 1.8814 7.1191
C3AR1 complement component 3a receptor 1 0.002707 4.5817 6.0814
MYD88 myeloid differentiation primary response gene (88) 0.002823 1.8194 8.0611
FCGR3B Fc fragment of IgG, low affinity IIIb, receptor (CD16b) 0.002868 4.1952 6.1543
SAMHD1 SAM domain and HD domain 1 0.003019 2.4624 5.7873
UBE2G1 ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, yeast) 0.003307 22.1036 6.9206
EGR1 early growth response 1 0.00334 3.2916 6.1035
MT1H metallothionein 1H 0.003445 2.0475 6.755
TPD52 tumor protein D52 0.003567 22.2114 7.0498
POU2AF1 POU domain, class 2, associating factor 1 0.00391 22.7707 8.0521
PPAPDC1B Phosphatidic acid phosphatase type 2 domain containing 1B 0.004347 22.3491 7.075
RP1-93H18.5 hypothetical protein LOC441168 0.004813 2.3726 8.0818
SIDT2 SID1 transmembrane family, member 2 0.00485 1.9548 8.3433
GBP1 guanylate binding protein 1, interferon-inducible, 67 kDa///guanylate binding
protein 1, interferon-inducible, 67 kDa
0.004938 2.3334 7.0136
GBP1 guanylate binding protein 1, interferon-inducible, 67 kDa 0.005006 2.4888 7.5899
LOC96610///IGL@ Hypothetical protein similar to KIAA0187 gene product///Immunoglobulin lambda locus 0.005057 22.9244 7.0226
HSP90B1 heat shock protein 90 kDa beta (Grp94), member 1 0.005488 21.9074 8.2753
CRR9 cisplatin resistance related protein CRR9p 0.006054 21.8843 7.3673
NDUFB6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17 kDa 0.006174 21.828 7.2738
RNASET2 ribonuclease T2 0.006686 2.0165 7.819
GBP2 guanylate binding protein 2, interferon-inducible///guanylate binding protein 2,
interferon-inducible
0.007125 1.8139 7.6419
EGR1 Early growth response 1 0.007242 4.6155 6.0488
CD97 CD97 molecule 0.007485 2.2044 6.8153
TYROBP TYRO protein tyrosine kinase binding protein 0.007507 2.8639 7.711
CTA-246H3.1 similar to omega protein 0.007524 22.578 8.6364
SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 0.00763 2.463 7.455
FGL2 fibrinogen-like 2 0.007811 2.6573 7.5789
TUBA3 tubulin, alpha 3 0.008598 1.8686 8.6244
TNFRSF17 tumor necrosis factor receptor superfamily, member 17 0.009406 22.7543 7.2692
GMNN geminin, DNA replication inhibitor 0.009426 22.2142 7.1972
SMC4L1 SMC4 structural maintenance of chromosomes 4-like 1 (yeast) 0.009866 22.2396 6.6128
FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog 0.009879 2.1941 7.2555
TNFSF13///TNFSF12-
TNFSF13
tumor necrosis factor (ligand) superfamily, member 13///tumor necrosis factor
(ligand) superfamily, member 12-member 13
0.010068 2.352 6.3382
IGL@ Immunoglobulin lambda locus 0.010428 22.6368 6.334
GNAS GNAS complex locus 0.010903 21.8682 8.2788
UAP1 UDP-N-acteylglucosamine pyrophosphorylase 1 0.010949 21.9816 6.8578
ARMET arginine-rich, mutated in early stage tumors 0.011018 21.8831 7.4254
--- Immunoglobulin kappa light chain (IGKV) mRNA variable region, joining region, and
constant region///Immunoglobulin kappa light chain (IGKV) mRNA variable region,
joining region, and constant region
0.011066 22.6563 7.408
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HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 0.011235 1.9378 7.2184
IGKV1D-13///
LOC649876
immunoglobulin kappa variable 1D-13///similar to Ig kappa chain V-I region
HK102 precursor
0.011292 22.3235 7.5191
PYCARD PYD and CARD domain containing 0.011531 1.904 7.3968
KIAA1505 KIAA1505 protein 0.011735 2.152 7.5726
SEC11L3 SEC11-like 3 (S. cerevisiae) 0.011854 22.0503 6.9297
CX3CR1 chemokine (C-X3-C motif) receptor 1 0.012371 2.3472 7.8999
MT1E metallothionein 1E (functional) 0.012654 1.8414 6.5549
CFD complement factor D (adipsin) 0.013175 2.7446 6.5182
C11orf75 chromosome 11 open reading frame 75 0.013342 2.1468 6.628
SRPRB signal recognition particle receptor, B subunit 0.01398 21.8251 7.2025
SAMD9L sterile alpha motif domain containing 9-like 0.01406 2.3893 7.1224
RP1-93H18.5 hypothetical protein LOC441168 0.014525 3.2665 6.6864
PACAP proapoptotic caspase adaptor protein 0.015153 22.4229 7.0357
KIAA0746 KIAA0746 protein 0.015464 22.0754 7.0611
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 0.015645 2.4265 7.8066
PRDX4 peroxiredoxin 4 0.01571 21.8982 7.3706
--- Transcribed locus 0.016136 21.9733 6.7522
LOC652745 similar to Ig kappa chain V-I region Walker precursor 0.016187 22.6756 7.035
TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box) 0.016262 1.8697 8.0753
--- Immunoglobulin kappa chain, V-region (SPK.3) 0.01639 22.3461 6.3625
PACAP proapoptotic caspase adaptor protein 0.016535 22.367 7.8079
ITM2C integral membrane protein 2C///integral membrane protein 2C 0.016602 21.9904 6.6164
C9orf19 chromosome 9 open reading frame 19 0.0169 1.9849 6.9941
LRRC59 leucine rich repeat containing 59 0.017101 21.8304 7.1703
S100A9 S100 calcium binding protein A9 (calgranulin B) 0.017515 2.0885 8.328
SPTLC2 serine palmitoyltransferase, long chain base subunit 2 0.017518 1.9835 7.0682
PARP12 poly (ADP-ribose) polymerase family, member 12 0.017657 1.9566 7.7735
S100A6 S100 calcium binding protein A6 (calcyclin) 0.019028 2.0002 7.2831
PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional
peptidase 2)
0.00005 1.5788 8.4562
MT2A metallothionein 2A 0.000184 1.7931 8.322
PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) 0.000465 21.4445 7.5556
NCL nucleolin 0.000569 21.5782 7.7589
HLA-F major histocompatibility complex, class I, F 0.000621 1.43 8.4362
MRLC2 myosin regulatory light chain MRLC2 0.001244 1.2847 8.6979
LRRFIP1 leucine rich repeat (in FLII) interacting protein 1 0.001476 1.4494 8.7862
IFITM1 interferon induced transmembrane protein 1 (9–27) 0.001576 1.5969 8.6038
ATP6V0E ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e 0.00176 1.3477 8.9288
CHSY1 carbohydrate (chondroitin) synthase 1 0.001841 1.4027 7.8411
C20orf118 Chromosome 20 open reading frame 118 0.001886 1.6089 8.5961
CD53 CD53 molecule 0.00198 1.3513 8.7833
C20orf118 Chromosome 20 open reading frame 118 0.001997 1.5776 8.6481
ATP6V0E ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e 0.00176 1.3477 8.9288
ATP6V0E ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e 0.002317 1.3355 8.2173
PIK3AP1 phosphoinositide-3-kinase adaptor protein 1 0.002432 1.784 7.8028
ADAR adenosine deaminase, RNA-specific 0.002492 1.3729 8.6116
METTL7A methyltransferase like 7A 0.002606 21.585 7.6029
GCH1 GTP cyclohydrolase 1 (dopa-responsive dystonia) 0.002631 1.6161 8.327
SELPLG selectin P ligand 0.002757 1.5125 7.4685
Table 2. Cont.
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WSB1 WD repeat and SOCS box-containing 1 0.00276 1.4536 8.0606
SQRDL sulfide quinone reductase-like (yeast) 0.003312 1.4912 7.7882
CXXC5 CXXC finger 5///CXXC finger 5 0.003382 21.6791 7.2149
FN5 ... 0.013342 2.1468 6.62795
LOC441168 ... 0.004813 2.3726 8.08179
SEC11L3 SEC11-like 3 (S. cerevisiae) 0.011854 22.0503 6.92968
LOC91353 ... 0.007524 22.578 8.63641
IGLC2 immunoglobulin lambda constant 2 (Kern-Oz- marker) 0.010428 22.6368 6.33398
TRA1 tumor rejection antigen (gp96) 1 0.005488 21.9074 8.2753
H3F3B H3 histone, family 3B (H3.3B) 0.018645 1.2441 9.03523
SFRS5 splicing factor, arginine/serine rish-5 0.027215 1.2557 8.35184
TMBIM4 transmembrane BAX inhibitor 0.310843 1.1017 8.58976
RHOA ras homolog gene family 0.016069 1.1702 8.59283
XRN1 59-39 exoribonuclease 1 0.007922 1.3637 8.3903
SAP18 sin3-associated polypeptide, 18 kDa 0.150022 21.1034 7.88139
ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 0.161681 1.1065 7.99103
HLA-B major histocompatibility complex, class I, B 0.060992 1.2255 9.22158
DEK DEK oncogene (DNA binding) 0.098052 1.1739 8.34219
EIF4A2 eukaryotic translation initiation factor 4A, isoform 2 0.27169 1.0921 8.68518
doi:10.1371/journal.pone.0007892.t002
Table 2. Cont.
Figure 3. Volcano plot showing p-values correlated to fold changes in DF vs DHF samples. The genes highlighted in red and blue
represent the top 40 genes according to the p-values and fold change respectively.
doi:10.1371/journal.pone.0007892.g003
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of both genes is a signature for DHF, whereas higher expression of
both genes is a signature for DF.
Validation of Microarray Data Using Quantitative Real
Time PCR
Quantitative real time PCR assays were performed in order to
validate the results seen on the microarray assay. The following
genes that were selected: PSMB9, MT2A, HLA-F and C3aR1,
displayed expression levels that were predominantly increased in
DF samples compared to DHF samples. Quantitative PCR of the
genes cited above was performed using eight DHF and eight DF
samples obtained from the same patients tested in microarray
experiments. According to the Figure 6A, the qPCR quantifica-
tions showed a very good correlation with the microarray data.
In addition, qPCR was performed in a separate set of eight
DHF and eight DF independent samples collected from a different
set of patients from the same cohort. The qPCR results indicated
that the level of expression of the genes selected was expressed at
lower levels in DHF than in DF patients, in agreement with the
results obtained with the 2D LDA model based on the microarray
data shown in Figure 5. Hence, each of the four genes measured
were expressed at lower level in DHF and they classified correctly
the samples analyzed (Figure 6B). These results are very
promising. We are confident that they can be the basis for a
successful development of a reliable classifier to predict the clinical
outcome of dengue infection.
Discussion
A functional genomic study was performed in order to obtain
insights about the early immune mechanisms associated with
dengue severity and to identify biomarkers to predict the infection
outcome. Initial analysis resulted in the selection of 1981 candidate
genes to be statistically evaluated. The analysis of degree of
similarity between the samples in a 2 and 3-dimensional spaces has
indicated that the DHF group formed a very tight pattern,
whereas the remaining groups were more dispersed in the plot. In
the 3-dimensional MDS plot the non-dengue samples (green
spheres) are grouped close together, with only one sample outlier.
The DHF samples (red spheres) are all at the far right side, while
the DF samples (blues spheres) are more spread apart. These
observations suggest the presence of a specific pattern of gene
regulation against a dengue virus infection when compared to
non-specific febrile disease. Welch’s two-sample t-tests were used
for comparisons among the diagnostic groups: Non-Dengue vs.
Dengue (DF+DHF) samples; DF vs. DHF samples and so on
Table 3. List of genes shown on the ‘‘Volcano’’ plot according to the fold-change.
Fold-change .2 Fold-change ,22
Symbol p value FC Symbol p value FC
S100A6 0.019028 2.0002 MAGED1 0.001644 22.0342
RNASET2 0.006686 2.0165 SEC11L3 0.011854 22.0503
MT1H 0.003445 2.0475 KIAA0746 0.015464 22.0754
S100A9 0.017515 2.0885 UBE2G1 0.003307 22.1036
FN5 0.013342 2.1468 TPD52 0.003567 22.2114
CD300A 0.000864 2.1544 GMNN 0.009426 22.2142
FGR 0.009879 2.1941 SMC4L1 0.009866 22.2396
CD97 0.007485 2.2044 UBE2J1 0.000419 22.3147
MT1X 0.001294 2.2122 IGKV1D-13 0.011292 22.3235
GBP1 0.004938 2.3334 PPAPDC1B 0.004347 22.3491
CX3CR1 0.012371 2.3472 PACAP 0.016535 22.367
TNFSF13 0.010068 2.352 PACAP 0.015153 22.4229
LOC441168 0.004813 2.3726 LOC91353 0.007524 22.578
SAMD9L 0.01406 2.3893 IGLC2 0.010428 22.6368
HLA-DPB1 0.015645 2.4265 TNFRSF17 0.009406 22.7543
SAMHD1 0.003019 2.4624 POU2AF1 0.00391 22.7707
SERPINA1 0.00763 2.463 IGLC2 0.005057 22.9244
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Statistically significant overrepresented functional categories (p,0.05), after adjusting for test multiplicity.
doi:10.1371/journal.pone.0007892.t004
Figure 4. Top 40 genes differentially expressed between DF and DHF samples. (A) Expression heatmap with GenBank annotations. (B)
Hierarchical clustering dendrogram (only top 40 genes). (C) 3-D MDS plot (only top 40 genes).
doi:10.1371/journal.pone.0007892.g004
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comparison between DHF versus DF.
The top 200 most differentially expressed genes between DF
and DHF cases according to Welch’s t-test was contrasted with the
list of the top 200 genes according to largest fold change of average
expression mRNA levels, resulting in 73 genes differentially
expressed among the dengue clinical manifestations that were
common to both lists. The list including all the 73 genes was
further analyzed using the EASE algorithm in order to identify
which categories of genes are overrepresented in this group of
genes. The statistically significant overrepresented functional
categories included the groups involved in immune and defense
responses (Table 2). Among the nineteen genes included in the
immune response category were the HLA-DPab genes, comple-
ment factor D, CX3CR, MyD88, TNFSF17 (BCMA), TNFSF13
(APRIL); and among the genes included in the defense response
were Mixovirus resistant gene (Mx), 29,5 9-oligoadenylate
synthetase (OAS1 and OAS2) and interferon response factors
(Supplement material S7), which were all less expressed in DHF.
While the immune and defense response genes were expressed at
lower levels in DHF, several genes associated with apoptosis
responses (PDCD4, PACAP, Tumor protein D52, MAGED1, pro-
apoptotic caspase adaptor protein and TNF ligand super family)
were up regulated. Interestingly, CD53, a tetraspanin produced by
monocytes and B cells that prevents cells from undergoing
apoptosis [40] was down regulated in DHF patients, reinforcing
the indication of a pro-apoptotic environment in DHF.
It is not unrealistic to expect that some of these genes could be
mechanistically involved in the DHF immunopathogenesis or
might be used as the basis for the prediction of dengue infection
severity. Using this technology, a gene expression pattern was
identified in patients suffering the most severe forms of the disease.
Simmons et all [27] have shown a molecular signature on PBMCs
discriminating early and late phases of DSS and they reported that
genes transcripts of IFN-stimulated genes were less abundant in
DSS patients than in patients without DSS, whereas the genes
involved on apoptosis were up-regulated in the DSS patients.
Some of the genes differentially expressed that were found by
Simmons et al [27], such as MX, IFIT, pro-apoptotic caspase
adaptor protein and OAS, were also found in this study. However,
they were not among the most significant differentially expressed
genes according to p-value in our study, perhaps because of
differences on the stage and severity of the disease. In this study
DHF patients were grades I or II and were compared to DF,
Table 5. Top 10 classifiers based on either individual, duplet
or triplet genes ranked by estimated classification error.
Classifiers
Gene 1 Gene 2 Gene 3 Estimated Error
1-Gene Classifiers
MT2A - - 0.0870
PSMB9 - - 0.0927
IGLC2 - - 0.1182
ADAR - - 0.1202
LOC400368 - - 0.1277
FCGR3B - - 0.1301
HLA-F - - 0.1314
CD53 - - 0.1365
VAMP3 - - 0.1389
CXXC5 - - 0.1443
2-Genes Classifiers
PSMB9 LRRFIP1 - 0.0351
H3F3B MT2A - 0.0496
SFRS5 PDCD4 - 0.0501
LRRFIP1 LOC400368 - 0.0504
PSMB9 MT2A - 0.0538
MT2A TMBIM4 - 0.0589
HA-1 LOC400368 - 0.0602
RHOA MT2A - 0.0603
MT2A XRN1 - 0.0635
MRLC2 LOC400368 - 0.0351
PSMB9 LRRFIP1 - 0.0496
H3F3B MT2A - 0.0501
SFRS5 PDCD4 - 0.0504
LRRFIP1 LOC400368 - 0.0538
3-Genes Classifiers
HNRPA1 PSMB9 MT2A 0.0256
LRRFIP1 MRLC2 LOC400368 0.0302
PSMB9 SAP18 LRRFIP1 0.0316
PSMB9 LRRFIP1 LOC400368 0.0319
ADAR PSMB9 ARHGEF6 0.0321
PSMB9 HLA-B MT2A 0.0323
LRRFIP1 RPS21 LOC400368 0.0324
DEK LRRFIP1 LOC400368 0.0326
EIF4A2 PSMB9 LRRFIP1 0.0326
DEK ADAR PSMB9 0.0329
doi:10.1371/journal.pone.0007892.t005
Figure 5. Classifier for the best pair of genes, PSMB9 and
MT2A, in the discrimination of DF against DHF. Lower expression
of both genes is a signature for DHF, whereas higher expression of both
genes is a signature for DF. The estimated probability of error on future
data for this classifier is only about 5.38%.
doi:10.1371/journal.pone.0007892.g005
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IV and were compared with DHF patients without DSS.
In a separate study, Ubol et al [28] using samples from a cohort
of children from Thailand obtained similar results associating
decreased innate immune response and increased apoptosis with
development of DHF. However, the individual genes identified
were quite different from the ones found in this and other studies.
One possible reason might be the age group used, since its known
that immune response repertoire differs during early ages, where
innate response predominates, as compared to adults [41]. In
another interesting study, Kruif et al (2008) reported a general
association of dengue severity and up regulation of genes involved
on innate immune response during acute phase of infection in
children [42]. However, in addition to the age group bias present
Figure 6. Expression levels of genes discriminating DF and DHF patients. A- For all tested genes, qPCR assays were performed using a mix
of eight DF or eight DHF samples used in microarray assays. B- For all tested genes, qPCR assays were performed for a set of eight DF and eight DHF
samples used in microarray assays (white solid columns), or a set of eight DF and eight DHF independent samples (grey solid columns). The
experiment was performed twice and each group was analyzed in triplicates.
doi:10.1371/journal.pone.0007892.g006
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leucocytes, which is composed predominantly by granulocytes,
and this most have contributed for the difference in findings. This
result suggests that granulocytes may be up-regulating the
expression of innate immune response genes whereas the
monocytic cells are suppressing it, but more detailed studies need
to be done simultaneously on specific cell populations of the same
patient. In summary, despite differences between the study designs
and differences in the genetic background of our populations our
results are consistent with the similar studies reported by Simmons,
Ubol and Kruif [27,28].
As reviewed by Clementini and Gianantonio [43], there is much
evidence that genetic factors, involved on susceptibility/resistance
to infectious disease, influence the immune response in humans.
These factors are complex traits modulated by environmental
factors, such as previous dengue infection, and do not follow
Mendelian inheritance pattern. The differential expression of
some of these markers are possibly due to genetic polymorphisms
that can interfere with mRNA expression levels, either directly by
sitting at the promoter or indirectly by interfering on the pathway
that modulates the transcription of those genes. Host polymor-
phisms present in genes involved in dengue immune responses
have been correlated with altered gene expression and suscepti-
bility to DHF [44]. Among these genes are: the TNF-308 allele,
which is associated with increased levels of TNFa, is correlated
with a greater susceptibility to developing DHF [45,46]; the wild-
type AA MBL2 genotype, which is correlated with increased levels
of MBL and increased risk factors for the development of dengue-
related thrombocytopenia [47] and the polymorphism of the
CD209 promoter [48], which is associated with a decreased
expression of DC-SIGN and possibly with a lower susceptibility of
dendritic cells to be infected by the dengue virus. Thus, searching
for gene expression alteration among different dengue clinical
manifestation using microarray technology can suggest in a high
throughput fashion, genetic factors and immunopathology mech-
anisms involved on dengue severity.
Moreover, during the acute phase of infection, patients suffering
from DF or DHF have a very similar clinical picture. However, the
disease defervescence period (after 4 to 7 days of the beginning of
the symptoms) is accompanied by severity-varying circulatory
disturbance signs [2]. Thus, it seems that the events preceding the
defervescence may determine the outcome of the disease severity
and a question of interest is the selection of a small set of the best
DHF-prognosis gene markers. The MDS plot (Figure 2) including
the top 40 most discriminatory genes according to p-value shows
that expression patterns of DF and DHF patients are quite
different and appear to be distributed into three groups; one DHF
(red) group very distinct from the DF (blue) cases, and a third
group, which DF and DHF are closer. This result is not surprising
and it suggests that DF and DHF are extremes of a continuum
spectrum of the same disease, as suggested by Sierra et al (2007),
and not two separate diseases [49]. In addition, this result suggests
the potential of designing a reliable classification marker based on
the quantification of few gene products by qPCR or any other
method to quantify RNA or protein products. Towards this goal,
we selected the best multivariate sets of candidate genes for
prognosis, by means of exhaustive feature selection (all possible
combinations) of single, pairs and triplets of genes out of the pre-
filtered set of 1981 genes, using Linear Discrimination Analysis as
the classification rule, and bolstered resubstitution as the error
estimator (see the Methods section). According to our results, the
top 3-gene classifiers displayed an estimated rate of more than
95% chance of correct classification. We selected a few genes
(PSMB9, MT2A, HLA-F and C3aR1) to test by qPCR assays.
Initially, the qPCR assays were performed in the same blood
samples used for the microarray study. All gene expression levels
determined by qPCR were consistent with the results obtained with
the microarray. Subsequently, qPCR quantification was performed
in eight DF and eight DHF samples collected from an independent
set of patients (Figure 6). The qPCR quantification showed that the
genes (PSMB9, MT2A, HLA-F and C3aR1) were expressed at
higher levels in DF than in DHF and confirmed the expression levels
seen on the first set patient samples used in the microarray study and
were in agreement with the 2D LDA model shown in Figure 4.
Hence, each of the four genes measured were expressed at lower
level in DHF and they classified correctly the samples analyzed
(Figure 5B). Thus, the qPCR assay results confirmed that
quantification of those genes in samples collected on the first medical
visit of a dengue infected patient can be used to predict whether the
individual will develop DHF symptoms two or three days later.
Our data indicates that the classification of patients into DF and
DHF on the basis of gene profiling is feasible and may be a useful
means of guiding clinical management of dengue patients. Further
analyses using additional independent samples are underway to
confirm the value of these classifiers. However, some points need
to be addressed on future studies, including the validation of the
gene markers identified here on samples collected from people
infected with other dengue serotypes for ultimately support the
development of a qPCR-based kit to predict the clinical outcome
of people infected with any of the dengue serotypes during the first
days of the symptoms. Besides the patient-management benefits,
this study can also help on the characterization of natural dengue
infection and hopefully will facilitate the elucidation of the
molecular mechanisms involved in DHF.
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DF vs. ND (B), DHF vs. ND (C) and DF vs DHF (D).
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Material S4 The top 40 genes with the most significant p-values
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